跳至主要内容
临床试验/NCT07659652
NCT07659652尚未招募不适用

Prospective Evaluation of Quality of Life in Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease

University of California, San Francisco1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2026年10月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
200
试验地点
1

研究概览

简要总结

Central nervous system (CNS) metastases including breast cancer brain metastases (BCBMs) and leptomeningeal disease (LMD) are common affecting up to 30% of patients with metastatic breast cancer (MBC). The goal of this research is to understand symptom burden and quality of life trajectories in this population and how treatments guide care management decisions.

详细描述

PRIMARY OBJECTIVE:

I. To describe overall symptom experience and quality of life (QOL) over time in breast cancer patients with brain metastases and/or leptomeningeal disease.

SECONDARY OBJECTIVES:

I. To evaluate the impact of cancer-directed treatments over time on quality of life, physical function, and cognitive function in patients with breast cancer brain metastases and/or leptomeningeal disease including:

  • The impact of whole brain radiation versus stereotactic radiosurgery on QOL.
  • The impact of brain metastasis surgical resection on QOL.
  • The impact of CNS-penetrant systemic therapies on QOL.
  • The impact of craniospinal irradiation and other treatment modalities for LMD on QOL.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be male or female 18 years of age or older.
  • Have stage 4 (metastatic) breast cancer with spread to the brain parenchyma and/or leptomeninges.
  • Have the intention to start or continue anticancer therapy.
  • Be able to provide informed consent.
  • Be able to speak and read English.

排除标准

  • Participants who are not on any anticancer therapy and are not planning to start any anticancer therapy will be excluded from the study.

结局指标

主要结局

未指定

次要结局

  • Changes in PROMIS - Cognitive function scores over time by non-investigational treatment regimen(Up to 5 years)
  • Changes in MDASI-BT scores over time by non-investigational treatment regimen(Up to 5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Quality of Life for Patients With Breast Cancer... | 临床试验